TAKE PROFITS ON MERCK — PFIZER ANTIVIRAL MORE EFFECTIVE AGAINST COVID

Twitter
LinkedIn
Facebook

By Nigam Arora & Dr. Natasha Arora

 

Being able to sell stocks correctly is as important as buying stocks correctly.  Most services and analysts get investors into stocks but do not get them out in a timely manner.

The Arora Report is the only reputable service of its kind that not only gives buy signals in real-time but also sell signals in real-time.

A recent example of the power of real-time signals from The Arora Report is the Merck (MRK)  trade.  Merck is one of the largest pharmaceutical companies in the world.

The Arora Report gave a signal to buy Merck in real-time before the stock ran up on the news that MRK had an antiviral drug effective against COVID.

By the time most analysts caught up and were giving buy signals, Merck stock had already run-up.  When the followers of other analysts were buying Merck stock at a much higher price, The Arora Report gave a signal to take partial profits.  Partial profits were taken near the highs.  Now Merck stock is falling because of the news that antiviral drug from Pfizer (PFE) is more effective than the Merck drug.  Pfizer drug also seems to have a better safety profile.

The Arora Report gave a signal in real-time to get subscribers out of the Merck trade at a profit.   Followers of other analysts are now sitting on a loss while their analysts are mum.

No wonder The Arora Report is popular among astute investors, investment advisors, and money managers.

The Arora Report has a long position in Pfizer stock.

To take a free 30-day trial to paid services to gain access to more opportunities, please click here.

Markets can generate substantial wealth for knowledgeable investors. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 2% of the content from our paid services. …TO RECEIVE REMAINING 98% INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES, TAKE A FREE
TRIAL TO PAID SERVICES.

Please click here to take advantage of a FREE 30 day trial.

Nigam Arora

Nigam Arora

Nigam Arora is known for his accurate stock market calls. Nigam is a distinguished master of the macro. He is a popular columnist with over 100 million page views, an engineer, and nuclear physicist by background. Nigam has founded two Inc. 500 fastest growing companies and has been involved in over 50 entrepreneurial ventures. He is the developer of Theory ZYX of Successful Change Management and is the author of the book on Theory ZYX, as well as the developer of the ZYX Change Method for Investing.

Dr. Natasha Arora

Dr. Natasha Arora

Dr. Natasha Arora has significant expertise in investment analysis especially biotech, healthcare, and technology. Natasha is a graduate of Harvard Medical School followed by a postdoc at MIT. She has published several peer reviewed research papers in top science journals.

Subscribe to 'Generate Wealth'

Free Forever

More To Explore

30 Day Free Trial

Cancel within 30 days and you owe nothing

When you take a FREE 30 day trial, you get access to powerful techniques used by billionaires and hedge funds to grow richer. You can continue to use these powerful techniques to grow richer even if you cancel your subscription. You come out ahead by subscribing no matter how you look at it.

A fortune is to be made from AI stocks.
Get the list of 18 AI stocks to grab your share of the profits — no cost to you.

A fortune is to be made from AI stocks.

Get the list of 18 AI stocks to grab your share of the profits.

AI is a $1 Trillion Market

Making A Fortune
In Artificial Intelligence

Golden Age of Artificial Intelligence